SCHEMBL4437685

SCHEMBL4437685

CS(=O)(=O)C[C@H](N)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.54
NOS2 P35228 1/20 0.52
KYNU Q16719 2/20 0.47
SLC1A3 P43003 5/20 0.46
SLC1A2 P43004 5/20 0.46
SLC1A1 P43005 4/20 0.46
GRIK1 P39086 4/20 0.46
GRIK2 Q13002 3/20 0.46
SLC7A5 Q01650 1/20 0.46
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GSR P00390 1/20 0.46
CYP1A2 P05177 1/20 0.46
GRM5 P41594 1/20 0.46
GRIA1 P42261 1/20 0.46
GRIA2 P42262 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7873430 1.00 PMP22 (0.54) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL17613156 1.00 PMP22 (0.54) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL18782794 0.82 PMP22 (0.50) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL18782774 0.82 PMP22 (0.50) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL18782571 0.82 PMP22 (0.50) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL20739371 0.81 PMP22 (0.50) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL8736543 0.81 PMP22 (0.67) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL24485485 0.80 NOS2 (0.39) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL15946195 0.80 NOS2 (0.39) PMP22NOS2KYNUSLC1A3SLC1A2
SCHEMBL8778376 0.80 NOS2 (0.39) PMP22NOS2KYNUSLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329502-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) JAPAN ENERGY CORPORATION (JP) 2001-12-11 US claimed
US-6313094-B1 COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION JAPAN ENERGY CORPORATION (JP) 2001-11-06 US claimed
US-5541290-A OLIGOPEPTIDE CONTAINING ALPHA-KETOAMIDE GROUP, TREATMENT OF ALZHEIMER*S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS CORTEX PHARMACEUTICALS, INC. 1996-07-30 US claimed
WO-1995000535-A1 OPTICALLY PURE CALPAIN INHIBITOR COMPOUNDS ALKERMES, INCORPORATED (US) 1995-01-05 WO claimed
EP-4734770-A1 COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2026-05-06 EP disclosed
WO-2025006362-A1 COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2025-01-02 WO disclosed
US-11149066-B2 Thrombospondin 1-binding peptide DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-10-19 US disclosed
US-11008287-B2 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine EPICENTRX, INC. (US) 2021-05-18 US disclosed
US-10668175-B2 Cathepsin-binding compounds bound to a carrier and their diagnostic use J. STEFAN INSTITUTE (SI) 2020-06-02 US disclosed
US-20200157047-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE EPICENTRX, INC. 2020-05-21 US disclosed
US-20200131230-A1 THROMBOSPONDIN 1-BINDING PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-04-30 US disclosed
WO-2018071741-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE EPICENTRIX, INC. (US) 2018-04-19 WO disclosed
US-5658939-A PREVENTION THROMBOSIS IN MAMMALS CORVAS INTERNATIONAL INC. (US) 1997-08-19 US disclosed
US-5646165-A ANTITHROMBOTIC AGENTS CORVAS INTERNATIONAL, INC. (US) 1997-07-08 US disclosed
EP-0765340-A1 METHIONINE SULFONE AND S-SUBSTITUTED CYSTEINE SULFONE DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-04-02 EP disclosed
US-5541290-A OLIGOPEPTIDE CONTAINING ALPHA-KETOAMIDE GROUP, TREATMENT OF ALZHEIMER*S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS CORTEX PHARMACEUTICALS, INC. 1996-07-30 US disclosed
WO-1995028420-A1 METHIONINE SULFONE AND S-SUBSTITUTED CYSTEINE SULFONE DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1995-10-26 WO disclosed
WO-1995000535-A1 OPTICALLY PURE CALPAIN INHIBITOR COMPOUNDS ALKERMES, INCORPORATED (US) 1995-01-05 WO disclosed
EP-0490667-A2 HIV protease inhibitors JAPAN ENERGY CORPORATION (JP) 1992-06-17 EP disclosed
US-4247543-A OLIGOPEPTIDES; ANALGESICS; NERVOUS SYSTEM DISORDERS SANDOZ LTD. (CH) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10668175-B2 Cathepsin-binding compounds bound to a carrier and their diagnostic use CTSB, CTSV, CTSE PMP22 1626/4885NOS2 3870/4885KYNU 2892/4885
US-11149066-B2 Thrombospondin 1-binding peptide SERPINC1, TEK, ARGLU1 PMP22 2282/4885NOS2 1755/4885KYNU 2137/4885
US-20200131230-A1 THROMBOSPONDIN 1-BINDING PEPTIDE SERPINC1, TEK, ARGLU1 PMP22 2282/4885NOS2 1755/4885KYNU 2137/4885
US-11008287-B2 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine AS3MT, SLC10A6, SLCO1B3 PMP22 30/4885NOS2 2640/4885KYNU 52/4885
US-20200157047-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE AS3MT, SLC10A6, SLCO1B3 PMP22 30/4885NOS2 2640/4885KYNU 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.